During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.

Julie Gralow, MD, shed light on the factors contributing to the growing shortage of oncologists in the US and what can be ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

An expert discusses using sequence therapies based on disease progression, patient factors, and resistance mechanisms. After a first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor ...

Panelists discuss how combining systemic therapy with locoregional treatments like transarterial chemoembolization (TACE) aims to enhance therapeutic efficacy by addressing its limitations, such as ...

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), particularly for patients with progressive or extensive disease. In locally ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.